Immunovant, Inc.IMVTNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+32.7%
5Y CAGR+35.1%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+32.7%/yr
vs +2511.2%/yr prior
5Y CAGR
+35.1%/yr
Consistent
Acceleration
-2478.5pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
4.5x
Strong expansion
Streak
7 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $487.17M | +11.2% |
| 2025 | $438.15M | +62.2% |
| 2024 | $270.21M | +29.7% |
| 2023 | $208.28M | +33.5% |
| 2022 | $156.03M | +44.3% |
| 2021 | $108.12M | +81.2% |
| 2020 | $59.66M | +13316194.6% |
| 2019 | $448.00 | -100.0% |
| 2018 | $136.74M | - |